Elanco Animal Health Inc

Elanco Animal Health Inc(ELAN)股票分析

$22.690

+0.141 (+0.62%)收盘时

Loading chart…
最高
22.842
开盘
22.430
成交量加权均价
22.63
成交量
4.45M
市值
7.05B
最低
22.350
成交额
100.75M
企业价值/息税折旧摊销前利润(TTM)
12.69

Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep.

AI 分析 of Elanco Animal Health Inc (ELAN)

买入

Elanco Animal Health Inc is a good buy right now due to its current price of $23.55, which is significantly lower than the median analyst price target of $32, indicating a potential upside of 31.3%. Additionally, the company's gross margin has improved to 48.17% in Q2 2026, reflecting strong operational efficiency. However, a risk to consider is the negative net income reported in Q4 2025 of -276 million USD, which highlights ongoing profitability challenges.

分析师评级(11)

上行空间 +12.38%
持有
5 买入
6 持有
0 卖出
当前: 22.69
最低
22.00
平均
25.50
最高
30.00

KeyBanc

2026-08-06

目标价

$30

增持

Citi

2026-08-06

目标价

$34

买入

Morgan Stanley

2026-07-22

目标价

$26

Equal Weight

TD Cowen

2026-06-18

目标价

$32

买入

Morgan Stanley

2026-05-15

目标价

$23

Equal Weight

估值指标

Elanco Animal Health Inc(ELAN)当前预期市盈率为 17.36,5 年平均预期市盈率为 17.68。

预期市盈率

合理
5 年均值 P/E
17.68
当前P/E
17.36
高估
21.99
低估
13.38

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
13.63
当前EV/EBITDA
12.69
高估
16.46
低估
10.80

预期市销率

合理
5 年均值 P/S
1.80
当前P/S
2.10
高估
2.36
低估
1.24

Alphio AI 对 ELAN 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%ELAN

$13.97

情景价格

基

基准

基准 · 50%ELAN

$13.55

情景价格

悲

悲观

悲观 · 25%ELAN

$10.58

情景价格

持有 ELAN 的大户

B

Blackhill Capital, Inc

+ 持有ELAN

+9.99%

3个月收益率

H

Hardman Johnston Global Advisors LLC

+ 持有ELAN

-2.05%

3个月收益率

B

Black Creek Investment Management Inc.

+ 持有ELAN

-3.55%

3个月收益率

事件时间线

2026-10-22 (ET)

07:30:00

Elanco Appoints Jamie Preston as Chief People Officer

2026-10-20 (ET)

12:30:00

U.S. 10-Year Treasury Yield Falls to Near One-Month Lows

2026-10-19 (ET)

16:30:00

Franklin Electric Appoints Luciana Amaro as Chief Human Resources Officer

2026-08-26 (ET)

09:00:00

Elanco Animal Health Completes 25,000-SF Manufacturing Expansion

2026-08-07 (ET)

15:00:00

Elanco Receives FDA Emergency Authorization for CLiK Extra to Prevent New World Screwworm Infestations

资讯

ELAN 常见问题 —— 由 Alphio AI 解答

Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Elanco Animal Health Inc is a good buy right now due to its current price of $23.55, which is significantly lower than the median analyst price target of $32, indicating a potential upside of 31.3%. Additionally, the company's gross margin has improved to 48.17% in Q2 2026, reflecting strong operational efficiency. However, a risk to consider is the negative net income reported in Q4 2025 of -276 million USD, which highlights ongoing profitability challenges.

11 analysts cover ELAN: 5 rate it Buy, 6 Hold and 0 Sell. The average price target is 25.50.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易